ConductScience.org, home

Paper666302

Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins.

Neu HC and 1 other. Antimicrob Agents Chemother, 1978. Cited by 75 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Papers, record 666302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/666302

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
75
iCite
Relative citation ratio, by iCite
3.44
iCite
Revised in PubMed
2021-05-26
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Neu HCH C
2Fu KPK P

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
CephalosporinsMajor topic
PenicillinsMajor topic
Aminoglycosides
Drug Synergism
Enterobacteriaceae
Microbial Sensitivity Tests
Pseudomonas

Source PubMed

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1190,540The nephrotoxicity of antimicrobial agents (second of three parts).N Engl J Med1977https://conductscience.org/library/papers/190540PubMed
2402,574The nephrotoxicity of antimicrobial agents (first of three parts).N Engl J Med1977https://conductscience.org/library/papers/402574PubMed
3320,483The nephrotoxicity of antimicrobial agents (third of three parts).N Engl J Med1977https://conductscience.org/library/papers/320483PubMed
4825,582Ticarcillin for treatment of serious infections with gram-negative bacteria.J Infect Dis1976https://conductscience.org/library/papers/825582PubMed
51,041,717Antibacterial activity of combinations of cefazolin and semisynthetic penicillins.J Antibiot (Tokyo)1975https://conductscience.org/library/papers/1041717PubMed
6984,795Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/984795PubMed
74,994,878Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.N Engl J Med1971https://conductscience.org/library/papers/4994878PubMed
8808,545The formation of functional penicillin-binding proteins.J Biol Chem1975https://conductscience.org/library/papers/808545PubMed
91,102,266Potent combinations of beta-lactam antibiotics using the beta-lactamase inhibition principle.Chemotherapy1975https://conductscience.org/library/papers/1102266PubMed
10791,104In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/791104PubMed

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 75 citations.

PMIDTitleJournalYearIn PapersSource
37,370,312Uncovering the Important Genetic Factors for Growth during Cefotaxime-Gentamicin Combination Treatment in blaCTX-M-1 Encoding Escherichia coli.Antibiotics (Basel)2023https://conductscience.org/library/papers/37370312PubMed
34,230,527A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms.Sci Rep2021https://conductscience.org/library/papers/34230527PubMed
33,268,776A bacteriocin-based antimicrobial formulation to effectively disrupt the cell viability of methicillin-resistant Staphylococcus aureus (MRSA) biofilms.NPJ Biofilms Microbiomes2020https://conductscience.org/library/papers/33268776PubMed
29,058,043Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria.Curr Microbiol2018https://conductscience.org/library/papers/29058043PubMed
7,095,864[Clinical experience with non-specific broad-spectrum antibacterial chemotherapy (author's transl)].Infection1982https://conductscience.org/library/papers/7095864PubMed
6,982,681Antibacterial activity and beta-lactamase stability of temocillin.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6982681PubMed
6,981,375In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6981375PubMed
6,454,388In vitro and in vivo antibacterial effects of combinations of beta-lactam antibiotics.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6454388PubMed
6,447,474Mezlocillin for treatment of infections in cancer patients.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/6447474PubMed
6,435,516In vitro activities of ureidopenicillins alone and in combination with amikacin and three cephalosporin antibiotics.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6435516PubMed
6,423,179Combinations of beta lactam antibiotics.Br Med J (Clin Res Ed)1984https://conductscience.org/library/papers/6423179PubMed
6,315,425Comparative synergistic activity of ceftriaxone-piperacillin versus ceftriaxone-netilmicin.Eur J Clin Microbiol1983https://conductscience.org/library/papers/6315425PubMed
6,255,862Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/6255862PubMed
6,218,105[Mezlocillin in neonatal medicine].Infection1982https://conductscience.org/library/papers/6218105PubMed
6,217,066Comparative synergistic activity of netilmicin-piperacillin versus gentamicin-piperacillin.Eur J Clin Microbiol1982https://conductscience.org/library/papers/6217066PubMed
6,214,995In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6214995PubMed
6,100,427In vitro activity and beta-lactamase stability of cefmenoxime.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6100427PubMed
3,634,545Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.Yale J Biol Med1986https://conductscience.org/library/papers/3634545PubMed
3,069,193Antibiotic combinations: should they be tested?Clin Microbiol Rev1988https://conductscience.org/library/papers/3069193PubMed
2,938,945Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.Eur J Clin Microbiol1986https://conductscience.org/library/papers/2938945PubMed

See all 22 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/666302

GET https://conductscience.org/api/papers/v1/666302/cited_by?page=2